Atara Biotherapeutics, Inc. (LON:0HIY)

Market Cap	25.85M -19.8%
Revenue (ttm)	113.03M +51.3%
Net Income	17.41M
EPS	1.46
Shares Out	n/a
PE Ratio	1.49
Forward PE	2.02
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,815
Average Volume	38,411
Open	4.850
Previous Close	4.630
Day's Range	4.580 - 4.930
52-Week Range	4.200 - 19.050
Beta	-0.40
RSI	26.97
Earnings Date	Feb 6, 2026

About Atara Biotherapeutics

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queenslan...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2012
• Employees: 38
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0HIY

Financial Performance

In 2024, Atara Biotherapeutics's revenue was $128.94 million, an increase of 1404.02% compared to the previous year's $8.57 million. Losses were -$85.40 million, -69.07% less than in 2023.

Financial numbers in USD